Corrigendum to pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study
Name:
Plimack, Powles - Corrigendum.pdf
Size:
315.2Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Plimack, ERPowles, T
Stus, V
Gafanov, R
Nosov, D
Waddell, Tom
Alekseev, B
Poulioti, F
Melichar, B
Soulieres, D
Borchiellini, D
McDermott, RS
Vynnychenko, I
Chang, YH
Tamada, S
Atkins, MB
Li, CX
Perini, R
Molife, LR
Bedke, J
Riniu, BI
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2023
Metadata
Show full item recordCitation
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023). EUROPEAN UROLOGY. 2023 NOV;84(5):E123-E4. PubMed PMID: WOS:001092250500001. English.Journal
European UrologyDOI
10.1016/j.eururo.2023.08.010PubMed ID
37666734Additional Links
https://dx.doi.org/10.1016/j.eururo.2023.08.010Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2023.08.010